Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry

EuroIntervention 2017;13:459-466 published online April 2017. DOI: 10.4244/EIJ-D-17-00092

Leonardo De Luca
Leonardo De Luca1*, MD, PhD, FACC, FESC; Fabrizio D’Ascenzo2, MD; Giuseppe Musumeci3, MD; Francesco Saia4, MD; Guido Parodi5, MD; Ferdinando Varbella6, MD; Alfredo Marchese7, MD; Stefano De Servi8, MD, FESC; Sergio Berti9, MD; Leonardo Bolognese10, MD, FESC; on behalf of the SCOPE Investigators
1. Division of Cardiology, San Giovanni Evangelista Hospital, Tivoli, Rome, Italy; 2. Division of Cardiology, Department of Internal Medicine, Città della Salute e della Scienza, Turin, Italy; 3. USC Cardiologia, Ospedale Santa Croce e Carle, Cuneo, Italy

Aims: In patients with acute coronary syndromes (ACS) undergoing a percutaneous coronary intervention (PCI), switching of oral P2Y12 receptor inhibitors may fr

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

adjunctive pharmacotherapymyocardial infarction
Coronary interventionsSTEMINSTEMIAdjunctive pharmacotherapyAdjunctive pharmacotherapy
Read next article
Left ventricular function determines the survival benefit for women over men after transcatheter aortic valve implantation (TAVI)

Latest news